<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; epithelial growth factory receptor</title>
	<atom:link href="http://oralcancernews.org/wp/tag/epithelial-growth-factory-receptor/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer</title>
		<link>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 02:52:02 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epithelial growth factory receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7393</guid>
		<description><![CDATA[Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

